UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next
UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next
Read moreFri, 19th Mar 2021 07:50
UK BROKER RATINGS SUMMARY: Shore Says Buy Hargreaves; UBS Cuts Next
Read moreBy Alistair SmoutLONDON, Dec 8 (Reuters) - Britain's initial doses of the COVID-19 vaccine candidate developed by AstraZeneca and Oxford University will come from Europe rather than a domestic supply chain, the country's Vaccine Taskforce said.The...
Read moreUK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell
Read moreOxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development
Read more(Sharecast News) - Gene and cell therapy group Oxford Biomedica has inked a discovery collaboration agreement with UK-based biopharmaceutical company PhoreMost.
Read moreUK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec
Read more(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Friday that partner Axovant Gene Therapies had pushed out the start date for its trial into a Parkinson's disease treatment.
Read moreUK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million
Read moreOxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD
Read moreAnother Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval
Read moreLONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development
Read moreLONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance
Read more(Sharecast News) - Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.
Read moreOxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal
Read moreLONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE
Read more